Logos Global Management LP Morpho Sys Ag Transaction History

Logos Global Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.55 - $9.9 $2.39 Million - $5.2 Million	525,000 Added 55.26%	1,475,000 $14.6 Million
Q3 2023 Nov 14, 2023	SELL	$6.72 - $8.6 $1.68 Million - $2.15 Million	-250,000 Reduced 20.83%	950,000 $6.38 Million
Q2 2023 Aug 14, 2023	SELL	$3.95 - $7.74 $1.19 Million - $2.32 Million	-300,000 Reduced 20.0%	1,200,000 $8.96 Million
Q1 2023 May 15, 2023	BUY	$3.56 - $5.22 $2.14 Million - $3.13 Million	600,000 Added 66.67%	1,500,000 $5.94 Million
Q4 2022 Feb 14, 2023	BUY	$3.21 - $5.74 $2.89 Million - $5.17 Million	900,000 New	900,000 $3.22 Million

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.54B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.